{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:35:03Z","timestamp":1771054503131,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd000206.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000}}],"reference-count":111,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000206.pub4","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T14:15:49Z","timestamp":1522073749000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Calcium channel blockers for antipsychotic-induced tardive dyskinesia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Adib","family":"Essali","sequence":"first","affiliation":[{"name":"Counties Manukau Health; Community Mental Health; Building 6, 17 Lambie Drive, Manukau Auckland New Zealand 2241"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Soares-Weiser","sequence":"additional","affiliation":[{"name":"Cochrane; Editorial & Methods Department; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"10.1002\/14651858.CD000206.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00004714-199202000-00007","article-title":"Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial","volume":"12","author":"Loonen","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0002|cit2","unstructured":"Loonen AJM van Bavel LP Hoekstra M Is diltiazem effective against the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A double-blind, restrictedly randomized, placebo-controlled, fixed-dosage, cross-over trial Clinical trial report"},{"issue":"1-2","key":"10.1002\/14651858.CD000206.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0920-9964(97)82352-3","article-title":"Effect of nifedipine on motor skill learning in schizophrenia","volume":"24","author":"Schwartz","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00002826-199708000-00009","article-title":"Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia","volume":"20","author":"Schwartz","year":"1997","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0005|cit5","first-page":"183","article-title":"A double-blind trial of flunarizine therapy for tardive dyskinesia","volume":"3","author":"Zeng","year":"1994","journal-title":"Chinese Journal of Pharmaco Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD000206.pub4-BIB0006|cit6","first-page":"421","article-title":"Effects of calcium-channel antagonists on tardive dyskinesia and psychosis","volume":"24","author":"Adler","year":"1988","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1192\/bjp.133.2.143","article-title":"Serum calcium and magnesium in schizophrenia: relationship to clinical phenomena and neuroleptic treatment","volume":"133","author":"Alexander","year":"1978","journal-title":"British Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD000206.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/archpsyc.1979.01780120102012","article-title":"Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms","volume":"36","author":"Alexander","year":"1979","journal-title":"Archives of general psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00004714-198308000-00002","article-title":"Serum calcium and magnesium levels in chronic schizophrenics","volume":"3","author":"Athanassenas","year":"1983","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD000206.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.4088\/JCP.v69n1007","article-title":"Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia","volume":"69","author":"Bisol","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0924933800005289","article-title":"Treatment of drug-resistant chronic schizophrenics with an association of neuroleptics and the calcium antagonist nimodipine","volume":"7","author":"Brambilla","year":"1992","journal-title":"European Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD000206.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.136.8.1035","article-title":"Calcium: pacesetting the periodic psychoses","volume":"136","author":"Carman","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0013|cit13","first-page":"11","article-title":"The significance of calcium antagonists and anticonvulsants for the pharmacotherapy of psychoses","volume":"1991","author":"Dose","year":"1991","journal-title":"Habilitationsschrift der Technischen Universitat Munchen"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00004714-199010060-00006","article-title":"Nifedipine in the treatment of tardive dyskinesia","volume":"10","author":"Duncan","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/hup.2289","article-title":"Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia","volume":"28","author":"Egan","year":"2013","journal-title":"Human Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/sj.mp.4001907","article-title":"Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin","volume":"12","author":"Ehrenreich","year":"2007","journal-title":"Molecular Psychiatry"},{"issue":"8589","key":"10.1002\/14651858.CD000206.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(88)91684-4","article-title":"Diltiazem for tardive dyskinesia and tardive dystonia","volume":"331","author":"Falk","year":"1988","journal-title":"Lancet"},{"issue":"1-2","key":"10.1002\/14651858.CD000206.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0920-9964(97)82597-2","article-title":"The effect of nifedipine on akathisia and agitation in patients with movement disorders","volume":"24","author":"Fay-McCarthy","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"1-2","key":"10.1002\/14651858.CD000206.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0920-9964(97)82782-X","article-title":"The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients","volume":"24","author":"Fay-McCarthy","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD000206.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0006-3223(86)90132-0","article-title":"A negative, double-blind, placebo-controlled, clinical-trial of verapamil in chronic-schizophrenia","volume":"21","author":"Grebb","year":"1986","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000206.pub4-BIB0021|cit21","first-page":"152","article-title":"Trilafon in combination with nimodipine in the treatment of 30 senile patients with first-episode schizophrenia","volume":"23","author":"Huang","year":"2004","journal-title":"Herald of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD000206.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1176\/ajp.155.7.972","article-title":"Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial","volume":"155","author":"Janicak","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0924-977X(99)80514-8","article-title":"Nimodipine attenuates psychotigenic effects of ketamine in humans","volume":"9","author":"Krupitsky","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0024|cit24","unstructured":"Lara D Flunarizine for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0140-6736(88)91110-5","article-title":"Diltiazem for tardive dyskinesia","volume":"1","author":"Leys","year":"1988","journal-title":"Lancet"},{"issue":"2-3","key":"10.1002\/14651858.CD000206.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.schres.2010.02.682","article-title":"The addition of tiagabine to antipsychotic medication in the treatment of recent-onset schizophrenia by modification of developmental pruning of prefrontal circuitry","volume":"117","author":"Liebman","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0027|cit27","unstructured":"NCT00425815 A placebo-controlled trial of org 24448 (ampakine) added to atypical antipsychotics in patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00425815"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0028|cit28","unstructured":"NCT00469664 A double blind placebo controlled study of guanfacine adjunctive treatment to atypical antipsychotics for cognitive dysfunction in schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00469664"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0029|cit29","unstructured":"NCT00512070 Melatonin metabolism abnormality in patients with schizophrenia or schizoaffective disorder treated with olanzapine and melatonin dose finding for the correction of the metabolic abnormality clinicaltrials.gov\/ct2\/show\/NCT00512070"},{"issue":"5","key":"10.1002\/14651858.CD000206.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"549S","DOI":"10.1080\/07315724.2004.10719401","article-title":"The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia","volume":"23","author":"Nechifor","year":"2004","journal-title":"Journal of the American College of Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archpsyc.1987.01800140015002","article-title":"Clinical and biochemical effects of verapamil administration to schizophrenic patients","volume":"44","author":"Pickar","year":"1987","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000206.pub4-BIB0032|cit32","first-page":"28","article-title":"The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics","volume":"108","author":"Popov","year":"2008","journal-title":"Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia"},{"issue":"1-4","key":"10.1002\/14651858.CD000206.pub4-BIB0033|cit33","first-page":"577","article-title":"Antischizophrenia effects of verapamil","volume":"31","author":"Price","year":"1986","journal-title":"International Journal of Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0035|cit34","first-page":"225","article-title":"Antipsychotic effects of verapamil in schizophrenia","volume":"9","author":"Price","year":"1987","journal-title":"Hillside Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD000206.pub4-BIB0034|cit35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00004714-198710000-00020","article-title":"Use of verapamil to treat negative symptoms in schizophrenia","volume":"7","author":"Price","year":"1987","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02684961","article-title":"Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation","volume":"7","author":"Ricketts","year":"1995","journal-title":"Journal of Developmental and Physical Disabilities"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0037|cit37","first-page":"441","article-title":"Diltiazem hydrochloride for tardive dyskinesia","volume":"i","author":"Ross","year":"1987","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD000206.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0924-977X(95)90713-N","article-title":"Therapeutic effect of diltiazem in tardive dyskinesia","volume":"5","author":"Rzewuska","year":"1995","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0039|cit39","unstructured":"Rzewuska M Soucka K Therapeutic effect of diltiazem in tardive dyskinesia 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 - Oct 4; Venice, Italy 1995"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0091-3057(91)90157-W","article-title":"A clinical trial of nifedipine in schizophrenia and tardive dyskinesia","volume":"39","author":"Suddath","year":"1991","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"10","key":"10.1002\/14651858.CD000206.pub4-BIB0041|cit41","first-page":"26","article-title":"Propranolol and verapamil therapy antipsychotics due to sinus tachycardia control study","volume":"22","author":"Wang","year":"1995","journal-title":"Central Plains Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD000206.pub4-BIB0042|cit42","first-page":"336","article-title":"Propranolol vs verapamil in treating drug-induced sinus tachycardia","volume":"14","author":"Wei","year":"1995","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"20","key":"10.1002\/14651858.CD000206.pub4-BIB0043|cit43","first-page":"54","article-title":"Efficacy of nimodipine combined sulpiride treatment of the negative symptoms of schizophrenia","volume":"14","author":"Wei","year":"2008","journal-title":"International Medicine and Health Guidance News"},{"issue":"6","key":"10.1002\/14651858.CD000206.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00004714-199612000-00005","article-title":"Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study","volume":"16","author":"Yamada","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0045|cit45","first-page":"36","article-title":"Calcium as a proposed treatment for drug-induced extrapyramidal symptoms","volume":"4","author":"Yaryura","year":"1968","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Alabed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0048|cit48","volume-title":"Tardive dyskinesia: a task force report of the American Psychiatric Association","author":"American Psychiatry Association","year":"1992"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0050|cit50","volume-title":"Antipsychotic Drugs and their Side-Effects","author":"Barnes","year":"1993"},{"issue":"11","key":"10.1002\/14651858.CD000206.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1176\/ajp.143.11.1485a","article-title":"An anti-tardive-dyskinesia effect of verapamil","volume":"143","author":"Barrow","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD000206.pub4-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0055|cit55","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0056|cit56","first-page":"303","article-title":"Treatment of tardive dyskinesia with verapamil","volume":"8","author":"Buck","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0057|cit57","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology: the Fourth Generation of Progress","author":"Casey","year":"1994"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/106002809302700214","article-title":"Are calcium-channel blockers effective in the treatment of tardive dyskinesia?","volume":"27","author":"Cates","year":"1993","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0059|cit59","article-title":"Cochrane Collaboration Handbook","volume-title":"The Cochrane Library","author":"Clarke","year":"2003"},{"issue":"15","key":"10.1002\/14651858.CD000206.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/sim.1205","article-title":"Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD000206.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/sim.1206","article-title":"Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD000206.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/sim.1207","article-title":"Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0063|cit63","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0065|cit65","first-page":"59","article-title":"Psychiatric application of calcium-channel blocking drugs","volume":"6","author":"Dubovsky","year":"1988","journal-title":"Today's Therapeutic Trends"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/01.nrl.0000038585.58012.97","article-title":"Classification and treatment of tardive syndromes","volume":"9","author":"Fernandez","year":"2003","journal-title":"Neurologist"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0070|cit70","first-page":"263","article-title":"The crossover study","volume-title":"The Design and Analysis of Clinical Experiments","author":"Fleiss","year":"1984"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0072|cit72","unstructured":"GRADE Working Group, McMaster University GRADEpro 2014"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0074|cit74","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised Edition","author":"Guy","year":"1976"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02579355","article-title":"Effects of calcium channel blockers on tardive dyskinesia","volume":"6","author":"Hendrickson","year":"1994","journal-title":"Journal of Developmental and Physical Disabilities"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0077|cit77","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"12","key":"10.1002\/14651858.CD000206.pub4-BIB0078|cit78","first-page":"18","article-title":"The primacy of neuroleptic-induced D2 receptor hypersensitivity in tardive dyskinesia","volume":"13","author":"Hoerger","year":"2007","journal-title":"Psychiatry Online"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0080|cit80","volume-title":"Understanding and Treating Tardive Dyskinesia","author":"Jeste","year":"1982"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/schbul\/19.2.303","article-title":"Tardive dyskinesia","volume":"19","author":"Jeste","year":"1993","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0082|cit82","volume-title":"Positive And Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"11","key":"10.1002\/14651858.CD000206.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000206.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0087|cit87","volume-title":"Dementia Rating Scale (DRS)","author":"Mattis","year":"1988"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0091|cit91","first-page":"110","article-title":"Crossover trials","volume-title":"Clinical Trials. A Practical Approach","author":"Pocock","year":"1983"},{"issue":"4","key":"10.1002\/14651858.CD000206.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1176\/jnp.2007.19.4.484a","article-title":"Olanzapine-induced tardive dystonia successfully treated by tetrabenazine","volume":"19","author":"Rauchverger","year":"2007","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0093|cit93","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"17","key":"10.1002\/14651858.CD000206.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.1991.03470170090030","article-title":"Prospective study of tardive dyskinesia incidence in the elderly","volume":"266","author":"Saltz","year":"1991","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0095|cit95","first-page":"431","article-title":"Clinical research for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"7653","key":"10.1002\/14651858.CD000206.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJM198510173131606","article-title":"Calcium-antagonist drugs: receptor interactions that clarify therapeutic effects","volume":"313","author":"Snyder","year":"1985","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000206.pub4-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00004714-199102000-00006","article-title":"Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients","volume":"11","author":"Stedman","year":"1991","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD000206.pub4-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0105|cit105","first-page":"1831","article-title":"Clinical course and cellular pathology of tardive dyskinesia","volume-title":"Neuropsychopharmacology: The Fifth Generation of Progress","author":"Tamminga","year":"2002"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handbook of Clinical Neurology \/ Edited by P.J. Vinken and G.W. Bruyn"},{"key":"10.1002\/14651858.CD000206.pub4-BIB0107|cit107","volume-title":"Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects","author":"Wolf","year":"1988"},{"issue":"7","key":"10.1002\/14651858.CD000206.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Losing participants before trial ends erodes credibility of finding","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD000206.pub4-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Essali","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000206.pub4-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub2","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000206.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T07:47:32Z","timestamp":1658648852000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000206.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":111,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000206.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,26]]}}}